Home » Stocks » BYSI

BeyondSpring, Inc. (BYSI)

Stock Price: $9.83 USD 0.03 (0.26%)
Updated Apr 19, 2021 11:54 AM EDT - Market open
Market Cap 383.59M
Revenue (ttm) n/a
Net Income (ttm) -38.09M
Shares Out 39.14M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $9.83
Previous Close $9.80
Change ($) 0.03
Change (%) 0.26%
Day's Open 9.80
Day's Range 9.67 - 10.06
Day's Volume 94,475
52-Week Range 9.55 - 21.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone

2 weeks ago - GlobeNewsWire

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

3 months ago - GlobeNewsWire

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

3 months ago - GlobeNewsWire

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

4 months ago - GlobeNewsWire

BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone.

4 months ago - Seeking Alpha

- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone

4 months ago - GlobeNewsWire

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smar...

4 months ago - Insider Monkey

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...

4 months ago - GlobeNewsWire

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer...

4 months ago - GlobeNewsWire

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapi...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapi...

5 months ago - GlobeNewsWire

- Announced SEED Therapeutics Inc.(“SEED”)'s collaboration with Eli Lilly and Company(“Lilly”)

5 months ago - GlobeNewsWire

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer...

5 months ago - GlobeNewsWire

- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines -

5 months ago - GlobeNewsWire

Former Forty Seven and Roche Senior Executives to Support Partnering Efforts Former Forty Seven and Roche Senior Executives to Support Partnering Efforts

6 months ago - GlobeNewsWire

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology t...

6 months ago - GlobeNewsWire

Poster Presentation at ESMO Congress 2020 Demonstrates Plinabulin’s Early Onset Protection, with a CIN Effect Comparable to Pegfilgrastim, Plus Improved Platelet Counts and Reduced Bone Pain Poster Pres...

6 months ago - GlobeNewsWire

New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO

6 months ago - GlobeNewsWire

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology can...

7 months ago - GlobeNewsWire

BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention o...

7 months ago - GlobeNewsWire

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer thera...

7 months ago - GlobeNewsWire

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: GTHX, KPTI, URGN
7 months ago - Seeking Alpha

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: GTHX, KPTI, URGN
7 months ago - Seeking Alpha

Gilead Acquired Forty Seven in March 2020 for $4.9 Billion Gilead Acquired Forty Seven in March 2020 for $4.9 Billion

8 months ago - GlobeNewsWire

BeyondSpring's Plinabulin Offers Multiple Roadmaps (Via Multiple Geographies) To Becoming A Blockbuster

8 months ago - Seeking Alpha

- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -

8 months ago - GlobeNewsWire

Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4 Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ P...

9 months ago - GlobeNewsWire

BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

The company announced the pricing of a public offering of common stock.

9 months ago - The Motley Fool

-Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p

10 months ago - GlobeNewsWire

- PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN -

10 months ago - GlobeNewsWire

- Plinabulin in Combination with Neulasta Improves Dose and Regimen Compliance of TAC Chemotherapy Compared to Neulasta Alone -

10 months ago - GlobeNewsWire

- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC -

10 months ago - GlobeNewsWire

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology ...

11 months ago - GlobeNewsWire

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2019 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer ther...

11 months ago - GlobeNewsWire

The Potential for Superior and Rapid Onset Protection from Infection with Plinabulin-G-CSF Combination Marks First Significant Enhancement in Preventing Neutropenia in 30 Years The Potential for Superio...

11 months ago - GlobeNewsWire

- Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years -

1 year ago - GlobeNewsWire

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-on...

1 year ago - GlobeNewsWire

No matter which strategy is employed or what types of stocks are sought after, investors want to see returns. The post 7 ‘Strong Buy’ Stocks With Over 50% Upside Potential appeared first on InvestorPl...

Other stocks mentioned: EQT, ESTE, EVFM, MSON, PLYA, SQNS
1 year ago - InvestorPlace

Presentation at the 2020 ASCO-SITC Provides Strong Validation for Plinabulin as a Potent activator of the Innate Immune System Presentation at the 2020 ASCO-SITC Provides Strong Validation for Plinabuli...

1 year ago - GlobeNewsWire

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-onc...

1 year ago - GlobeNewsWire

Plinabulin Protects Bone Marrow from Chemotherapy-Induced Deficiencies with a Differentiated Yet Complimentary Mechanism to G-CSF for CIN Prevention Plinabulin Protects Bone Marrow from Chemotherapy-Ind...

1 year ago - GlobeNewsWire

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3 Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negati...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today anno...

1 year ago - GlobeNewsWire

The stock is down due to the recent share offering done at a 20% discount to market price.

1 year ago - Seeking Alpha

About BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab... [Read more...]

Industry
Biotechnology
IPO Date
Mar 9, 2017
Stock Exchange
NASDAQ
Ticker Symbol
BYSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for BeyondSpring stock is "Strong Buy." The 12-month stock price forecast is 33.25, which is an increase of 238.42% from the latest price.

Price Target
$33.25
(238.42% upside)
Analyst Consensus: Strong Buy